Scores gather in protest over Dresden, Ont., landfill project
Bill 5 was passed by the province on June 4 and gives Premier Doug Ford's government the power to suspend provincial and municipal laws for chosen projects in areas it deems to have economic importance.
Al Kominek, a local cash-crop farmer, said he and several other farmers have their farms right along the edge of the proposed landfill.
Kominek, who describes himself as a Conservative, said he's written to the premier to let him know he opposes Bill 5.
"I just sent a letter yesterday about just how unhappy I am about the whole thing," he told CBC News.
"Toronto doesn't care about our community but we do, and we should have a say and a right to complain about something that's just thrown upon us."
Kominek said he's "disheartened" for the people who live closest to the proposed landfill.
"They've been fighting so hard to prevent this from happening and all of a sudden they just show up," he said. "It's disheartening for everyone who lives in the community to see this."
The company responsible for the project — York1 Environmental Waste Solutions Ltd., based just outside Toronto — says a small crew has arrived in the area and prep work is underway for the landfill.
In an emailed statement to CBC Windsor, the company said everything being done is permitted under the site's existing environmental compliance approval.
The company also stressed that the site will not be used for household waste but for non-hazardous construction and demolition materials.
Ashley Khouathip, another resident, says she remains optimistic that Bill 5 would be rescinded.
"I think we're all still very hopeful. Bill 5 might have passed, but we're not done fighting," Khouathip said.
"There's still a lot of little things along the way that they need to set in stone before they can go full throttle."
Khouathip said a dump in the area is "going to affect us greatly, because the kids play out here. It's not like being in the city, they roam free, they fish, a lot of us kayak and we're on the water all the time."
Ontario NDP Leader Marit Stiles, who is on a three-day visit to Windsor and area, was also at the protest. She joined members of Dresden C.A.R.E.D. and Chatham-Kent municipal councillors to call on the Ford government to repeal Bill 5.
"This is not a partisan issue … but what really gets me about what's happening to Dresden is that this is a prime example of a government and a premier making another promise and commitment and breaking it," Stiles said.
Stiles assured residents and those at the protest rally that she will keep the issue alive in the provincial legislature.
"I want you to know that back at Queen's Park, where many of you have come to show your opposition to Bill 5, the voices of the people of Dresden and this area are echoing around the halls of Queens Park," she said.
Lyle Gall, a representative of the Public Service Alliance of Canada, said all workers in Canada should stand in opposition to Bill 5, which has sparked a fierce opposition and anger among First Nations.
"We stand in solidarity with Indigenous leaders who oppose this attack on their national sovereignty and treaty rights," he said.
"We will not stand for this direct attack on First Nations, we will not stand for this direct attack on workers, we will not stand for this direct attack on the land. We called for an immediate repeal of Bill 5," Lyle added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
XORTX Completes USD $114,500 Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 08, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ('XORTX' or the 'Company') (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the closing of its previously announced non-brokered private placement of units ('Units'), whereby it issued 156,849 Units at a price of US$0.73 per Unit for aggregate gross proceeds of US$114,500 (the 'Offering'). Under the Offering, each Unit consisted of one common share in the capital of the Company ('Common Share') and one common share purchase warrant ('Warrant'). Each Warrant entitles the holder thereof to purchase one additional Common Share at a price of US$1.20 for a period of sixty (60) months following the date of issuance provided, however, that if the closing price of the Common Shares on the Nasdaq is greater than US$2.00 for ten (10) or more consecutive trading days, the Warrants will be accelerated and will expire on the 30th business day following the date of such notice. Closing of the Offering was conditionally approved by the TSX Venture Exchange ('TSXV'), and the securities issued under the Offering are subject to a four-month and one-day statutory hold period. The Company intends to use the proceeds of the Offering for gout programs, general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The securities have not and will not be registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any applicable state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. persons,' as such term is defined in Regulation S promulgated under the U.S. Securities Act, absent registration or an exemption from such registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at For more information, please contact: Allen Davidoff, CEO Nick Rigopulos, Director of Communications adavidoff@ nick@ +1 403 455 7727 +1 617 901 0785 Forward Looking Statements Statements contained in this news release that are not historical facts are 'forward-looking information' or 'forward-looking statements' within the meaning of applicable Canadian securities laws. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as 'anticipate', 'proposed', 'estimates', 'would', 'expects', 'intends', 'plans', 'may', 'will', and similar expressions, although not all forward-looking information contains these identifying words. More particularly and without limitation, the forward-looking information in this news release includes (i) expectations regarding the Company's current and future financing plans; (ii) expectations concerning the Company's plans and objectives in respect of the Offering's gross proceeds; and (iii) expectations regarding the Company's business plans and operations. Forward-looking information is based on a number of factors and assumptions that have been used to develop such information, but which may prove to be incorrect and are inherently subject to significant business, economic and competitive uncertainties, and contingencies. The material factors and assumptions used in preparing the forward-looking information contained herein include, among others, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and our ability to obtain and maintain intellectual property protection for our product candidates. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this news release reflects the Company's current expectations, assumptions and/or beliefs based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading 'Risk Factors' in XORTX's Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.


Bloomberg
10 minutes ago
- Bloomberg
Indigenous Group Wins Land Claim Over Slice of Metro Vancouver
An Indigenous group won claim to hundreds of acres of metropolitan Vancouver after a years-long trial and landmark judgment at British Columbia's supreme court. The Cowichan have aboriginal title to a section of riverbank in the city of Richmond, according to the 863-page ruling published Friday. Interests of the government of Canada and the city in the area alongside the Fraser River outlined in black on a map attached to the ruling 'are defective and invalid,' the judge said.
Yahoo
11 minutes ago
- Yahoo
CLIFFORD L. RUCKER PROVIDES UPDATE ABOUT HOLDINGS OF FLOW BEVERAGE CORP.
This press release is issued pursuant to Multilateral Instrument 62-104 – Take-Over Bids and Issuer Bids and National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. TORONTO, Aug. 8, 2025 /CNW/ - This press release is being made by Clifford L. Rucker ("Mr. Rucker") to report information concerning holdings of RI Flow LLC (the "Investor"), NFS Leasing Canada Ltd. ("NFS Canada"), NFS Capital, LLC ("NFS") and Mr. Rucker in Flow Beverage Corp. (the "Issuer" or "Flow"). The Investor is directly owned by Mr. Rucker. NFS Canada is a wholly owned subsidiary of NFS and NFS is directly owned by Mr. Rucker. On June 4, 2025, the Issuer announced that it had entered into a secured convertible loan agreement with the Investor (the "Convertible Loan Agreement") pursuant to which the Investor agreed to advance a convertible loan of up to $6,000,000 to the Issuer (the "Convertible Loan"). The Convertible Loan bears interest at an annual rate of 15% and the principal balance and accrued interest (collectively the "Outstanding Balance") of the Convertible Loan are convertible into subordinate voting shares ("SVS") of the Issuer at a conversion price of $0.065 per share, entitling the Investor to convert up to 114,115,385 SVS, assuming that all Tranches (as defined below) of the Convertible Loan are advanced. The Investor is only permitted to convert the Outstanding Balance, (i) on or after June 2, 2026, (ii) upon and following a change of control of the Issuer or (iii) upon a divestiture of the Issuer's packaging facility in Aurora, Ontario and related operations (the "Conversion Eligibility Date"). As of the date of this press release, all three tranches have been advanced to Flow in accordance with the terms of the Convertible Loan Agreement. Each Tranche has been advanced with a principal amount of $2,000,000. The first of three tranches (the "First Tranche") was advanced to the Issuer on June 4, 2025, the second tranche (the "Second Tranche") was advanced to the Issuer on July 2, 2025, and the third and final tranche (the "Third Tranche", together with the First Tranche and Second Tranche, the "Tranches") was advanced to the Issuer on August 8, 2025. Current Holdings Prior to the date of this press release, the Investor owned, and Mr. Rucker beneficially owned or exercised control or direction over 12,050,000 SVS, and held the right to convert the Outstanding Balance into up to 76,076,923 SVS. NFS Canada also owned, and Mr. Rucker and NFS beneficially owned or exercised control or direction over, warrants exercisable into 5,345,380 SVS (the "Warrants"). Collectively, these holdings represented: On an undiluted basis: 14.31% of the issued and outstanding SVS, a 13.34% equity interest in the Issuer, and 8.29% of the voting rights attached to all of the Issuer's outstanding voting securities; and On a partially diluted basis (assuming exercise of the outstanding Warrants and conversion of the Outstanding Balance): 56.43% of the issued and outstanding SVS, a 54.42% equity interest in the Issuer, and 41.23% of the voting rights attached to all of the Issuer's outstanding voting securities. The forgoing percentages are calculated based on 84,226,014 SVS and 6,106,566 multiple voting shares ("MVS") issued and outstanding. Third Tranche of the Convertible Loan As of the date of this press release, the Issuer has met the conditions for funding as set out in the Convertible Loan Agreement and the Third Tranche has been advanced to the Issuer. As such, the Investor now owns, and Mr. Rucker beneficially owns, or has control or direction over 12,050,000 SVS and, after the Conversion Eligibility Date, will hold the right to convert the Outstanding Balance into up to 114,115,385 SVS. In addition, NFS Canada owns, and Mr. Rucker and NFS beneficially own or exercise control or direction over, warrants exercisable into 5,345,380 SVS. Collectively, these holdings represent: On an undiluted basis: 14.31% of the issued and outstanding SVS, a 13.34% equity interest in the Issuer, and 8.29% of the voting rights attached to all of the Issuer's outstanding voting securities; and On a partially diluted basis (assuming exercise of the outstanding Warrants and conversion of the Outstanding Balance): 64.57% of the issued and outstanding SVS, a 62.69% equity interest in the Issuer, and 49.67% of the voting rights attached to all of the Issuer's outstanding voting securities. The forgoing percentages are calculated based on 84,226,014 SVS and 6,106,566 MVS issued and outstanding. This Report references interest accruing on the principal balance of the Convertible Loan, which compounds on an annual basis from June 4, 2025, until the indefeasible payment thereof in full. Other Information The Investor and its affiliates may, from time to time, acquire additional securities of the Issuer and/or dispose of such securities as the Investor deems appropriate based upon market conditions, general economic and industry conditions, the trading price of the SVS, the Issuer's business, financial condition or prospects, and/or other relevant factors The Issuer head office is located at 155 Industrial Parkway South, Unit 7-10, Aurora, Ontario L4G 3G6, the Investor and Mr. Rucker are located at 500 Cummings Center, Suite 6050, Beverly, MA 01915. A copy of the report filed under applicable Canadian securities laws by the Investor in connection with the transactions referred to in this press release may be obtained from the Investor via email: legal@ or telephone (978) 338-6250. SOURCE Clifford L. Rucker View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data